Clinical trials of bevacizumab, a monoclonal antibody against vascular endothelial growth factor combined with doxorubicine, was conducted for soft tissue sarcomas, including uterine leiomyosarcoma [51]. The gene discussed is VEGFA; the disease is soft tissue sarcoma.